ArticleOpen forum infectious diseases2026
Characteristics, Treatment Strategies, and Long-term Health Outcomes of People With Bedaquiline-resistant Tuberculosis in Karakalpakstan, Uzbekistan-A Retrospective Cohort Study.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bedaquiline resistance is increasing globally, threatening effectiveness of short regimens for rifampicin/multidrug-resistant (RR/MDR)-tuberculosis. Limited data exist describing the treatment and long-term outcomes of people with bedaquiline-resistant tuberculosis. Methods: We did a retrospective cohort study of patients with bedaquiline-resistant tuberculosis in Karakalpakstan, Uzbekistan, from January 2017 until June 2025. Clinical and laboratory records were reviewed to describe treatment regimens, drug sensitivity profiles, and sputum results. We measured time to sustained sputum culture conversion (SCC), mortality, and the proportion of patients who had tuberculosis-free survival (alive, and had completed treatment or were in care, and had SCC) 18 months after bedaquiline resistance was detected. Results: Among 50 patients with bedaquiline-resistant tuberculosis who received treatment, the median age was 41 years (IQR: 27-52), 64% (32/50) were male, 69% (34/49) had fluoroquinolone resistance, and 32% (16/50) had not previously received bedaquiline. The median treatment duration was 18.8 months (IQR: 9.0-22.4), with bedaquiline prescribed for 84% for a median 5.6 months (IQR: 2.2-12.9), imipenem for 66% for a median 8.1 months (IQR: 4.5-11.3), and amikacin for 50% for a median 7.9 months (IQR: 4.4-11.1). The median time to SCC was 5.9 months (IQR: 2.1-15.9) and the probabilities of survival to 18 months and 5 years were 79.7% (95% CI: 69.2-91.8) and 63.4% (95% CI: 48.8-82.4). Of 48 patients who had an assessable 18-month outcome, 60.4% (29/48) had tuberculosis-free survival. Conclusions: Management of bedaquiline-resistant tuberculosis in Uzbekistan required prolonged antituberculosis therapy, often with injectables, resulting in delayed culture conversion and poor long-term health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.